NASDAQ: NVAXNovavax Inc Stock Ownership - Who owns Novavax?
Insider buying vs selling
Have Novavax Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| James Patrick Kelly | EVP CFO and Treasurer | 2025-03-07 | 5,904 | $8.34 | $49.24kSell |
| John Trizzino | President and COO | 2025-03-07 | 13,954 | $8.34 | $116.38kSell |
| Elaine Ohara | EVP Chief Strategy Officer | 2025-03-01 | 10,969 | $8.33 | $91.37kSell |
| Mark J. Casey | EVP Chief Legal Officer | 2025-03-01 | 1,214 | $8.33 | $10.11kSell |
| John C. Jacobs | President and CEO | 2025-03-01 | 38,451 | $8.33 | $320.30kSell |
| James Patrick Kelly | EVP CFO and Treasurer | 2025-03-01 | 28,337 | $8.33 | $236.05kSell |
| Elaine Ohara | EVP Chief Strategy Officer | 2025-03-01 | 5,375 | $8.33 | $44.77kSell |
| John Trizzino | President and COO | 2025-03-01 | 23,185 | $8.33 | $193.13kSell |
| John C. Jacobs | President and CEO | 2025-01-23 | 38,873 | $9.55 | $371.24kSell |
| James F. Young | Director | 2024-12-31 | 5,400 | $8.00 | $43.20kSell |
NVAX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when NVAX insiders and whales buy or sell their stock.
NVAX Shareholders
What type of owners hold Novavax Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Vanguard Group Inc | 9.50% | 15,433,212 | $147.85M | Institution |
| Blackrock Inc | 7.85% | 12,743,155 | $122.08M | Institution |
| Shah Capital Management | 7.09% | 11,511,780 | $110.28M | Institution |
| Cadila Pharmaceuticals Ltd | 5.85% | 9,500,000 | $91.01M | Insider |
| Sanofi | 4.24% | 6,880,481 | $65.92M | Institution |
| State Street Corp | 4.20% | 6,824,251 | $65.38M | Institution |
| James B. 1. Tananbaum | 3.86% | 6,268,455 | $60.05M | Insider |
| Sj Strategic Investments LLC | 2.46% | 4,001,500 | $38.33M | Insider |
| D E Shaw Co Inc | 2.43% | 3,940,960 | $37.75M | Institution |
| Coatue Management LLC | 2.36% | 3,836,986 | $36.76M | Institution |
NVAX vs Biotech Stocks
Novavax Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.